B&L Unit To Pay $34M For Drug Marketing Guilty Plea: DOJ

Law360, New York (May 24, 2013, 7:16 PM EDT) -- A Bausch & Lomb Inc. affiliate will cough up $33.5 million as part of an agreement copping to federal charges that it promoted an anti-inflammatory eye-treatment drug for unapproved new uses that were billed to federal health programs, the U.S. Department of Justice said Friday.

Ista Pharmaceuticals Inc. pled guilty to conspiracy to introduce a misbranded drug into the marketplace based on federal allegations that the Ista employees illegally pushed for the use of Xibrom after Lasik and glaucoma surgeries. The drug is approved by the...
To view the full article, register now.